AS
ASTH.WA
—
Warsaw Stock Exchange
Fishing & Farming
Asth.Wa
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
4,26 %
Op margin
—
ROE
—
Net margin
—
Debt / equity
0,48
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$49,81
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
ASTH.WA operates in the Food & Beverages sector, specifically in the Fishing & Farming industry, and generates revenue primarily through the production and sale of food products.
Business. ASTH.WA operates in the Food & Beverages sector, specifically in the Fishing & Farming industry, and generates revenue primarily through the production and sale of food products.
Classification92 %
SectorConsumer Non-Cyclicals
Business sectorFood & Beverages
IndustryFishing & Farming
ActivityFood
Generated · model-assisted
Sell-side consensus
BUY11 analysts
10 buy1 hold0 sell
Avg 12m price target47,11
Analyst recommendations
11 analysts · consensus BuyBuy10
Hold1
Sell0
12-month price target
47,11
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
11 analysts · indicative
Ownership
—
not yet wired
Profitability
—
not yet wired
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ASTH.WA. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressJudy Chu — Astrana Health Inc. - Common Stock2025-08-19 · Democrat · CA · Sale · $100,001 - $250,000
- CongressJudy Chu — Astrana Health Inc. - Common Stock2025-08-19 · Democrat · CA · Purchase · $100,001 - $250,000
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
ASTH.WA operates in the Food & Beverages sector, specifically in the Fishing & Farming industry, and generates revenue primarily through the production and sale of food products.
Classification92 %
SectorConsumer Non-Cyclicals
Business sectorFood & Beverages
IndustryFishing & Farming
ActivityFood
AI synthesis
GENERATEDASTH.WA maintains a debt-to-equity ratio of 0.48, indicating a relatively conservative capital structure with equity significantly outweighing debt. The company's liquidity position is assessed as medium, with cash and equivalents amounting to 40.24 million EUR, which is less than its long-term debt of 266.71 million EUR, resulting in a net cash position that is negative after subtracting total debt.
In terms of profitability, ASTH.WA reported a revenue of 471.93 million EUR, which is below the mean revenue estimate of 19.48 billion EUR. The company's operating cash flow of 36.47 million EUR suggests it is generating positive cash from operations, but the capital expenditure of -102.21 million EUR indicates significant investment in long-term assets.
The company's revenue is concentrated within the Food & Beverages sector, with no disclosed geographic diversification provided in the available data. This lack of geographic segmentation may expose the company to regional economic fluctuations.
ASTH.WA's growth trajectory is mixed, with a reported revenue of 471.93 million EUR, which is significantly lower than the mean revenue estimate of 19.48 billion EUR. The company's capital expenditure of -102.21 million EUR suggests ongoing investment, which may support future growth.
The risk assessment for ASTH.WA indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet short-term obligations without additional financing.
Recent financial data and analyst estimates show that ASTH.WA's last actual EPS was 148.82 EUR, and the mean EBIT estimate is 2.09 billion EUR. These figures suggest that the company is performing well in terms of earnings but faces challenges in meeting revenue expectations.
Key takeaways
- ASTH.WA has a conservative capital structure with a debt-to-equity ratio of 0.48.
- The company's liquidity position is medium, with cash and equivalents less than its long-term debt.
- ASTH.WA's revenue is below the mean revenue estimate, indicating potential underperformance.
- The company is investing heavily in capital expenditures, which may support future growth.
- ASTH.WA faces a medium liquidity risk and a low dilution risk.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$56,00
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
—
Net cashⓘ
-$226.5M
Current ratioⓘ
—
Debt / equityⓘ
0.5
ROAⓘ
—
ROEⓘ
—
Cash conversionⓘ
—
CapEx / revenueⓘ
-21.7%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
1,27
Predicted surprise
+0,00
Beat probability
45 %
Analysts
11
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-07-02 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | —no estimate |
| Revenue | —no estimate | —no estimate | 19,5B EUR |
| Operating income | —no estimate | —no estimate | 2,1B EUR |
Full-year consensus mean (period as reported by source) · consensus in EUR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageOperating income · consensus2,1B EUR
Revenue surprise
+36,2 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$41,00
Mean$47,11
Median$47,00
High$53,00
Spot$56,00
−15.9 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Capex / Rev-21,7 %Bottom quartile
D/E0,48Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 132 338 sh6 exercises6 insiders
- CEO and President · Stock Option (right to buy) → Common StockDisposed 21 334 @ $23,24exercise · 2026-02-02
- Director · Stock Option (right to Buy) → Common StockDisposed 20 000 @ $5,79exercise · 2026-01-13
- Director · Stock Option (right to buy) → Common StockDisposed 29 502 @ $17,78exercise · 2025-12-08
- Director, Executive Chairman · Stock Option (right to buy) → Common StockDisposed 29 502 @ $17,78exercise · 2025-11-10
- Director · Stock Option (right to Buy) → Common StockDisposed 20 000 @ $18,20exercise · 2025-11-10
- Director · Stock Option (right to buy) → Common StockDisposed 12 000 @ $18,20exercise · 2025-11-07
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
Source documents
- ASTH.WA Market data — financials · 2026-05-27
- Astarta Holding PLC Market data — analyst estimates · 2026-05-27
Ownership & reference
Insider activity
Mixed / flat0 buys · 0 sellsnet $012 insiders · last 365d
- CEO and President · Common StockOther 1 093 @ $44,51$49K · 2026-06-27
- Director · Common StockOther 4 991 · 2026-06-10
- Director · Common StockOther 4 525 · 2026-06-10
- Director · Common StockOther 4 525 · 2026-06-10
- Director · Common StockOther 4 525 · 2026-06-10
- Director · Common StockOther 4 525 · 2026-06-10
- Director · Common StockOther 4 525 · 2026-06-10
- COO and CFO · Common StockOther 8 155 @ $38,26$312K · 2026-05-16
- COO and CFO · Common StockOther 3 870 @ $29,07$113K · 2026-04-14
- Director · Common StockOther 41 667 · 2026-04-06
- CEO and President · Common StockOther 201 056 · 2026-04-06
- Director, Executive Chairman · Common StockOther 100 000 · 2026-04-06
- COO and CFO · Common StockOther 2 092 @ $25,05$52K · 2026-04-02
- Chief Medical Officer · Common StockOther 57 980 @ $24,51$1,4M · 2026-04-01
- Chief Medical Officer · Common StockOther 35 300 · 2026-04-01
- Chief Accounting Officer · Common StockOther 662 @ $24,27$16K · 2026-03-26
- COO and CFO · Common StockOther 1 240 @ $25,07$31K · 2026-03-05
- Director · Common StockOther 9 266 @ $25,07$232K · 2026-03-05
- Chief Medical Officer · Common StockOther 1 697 @ $25,07$43K · 2026-03-05
- CEO and President · Common StockOther 21 334 @ $23,24$496K · 2026-02-02
- Chief Medical Officer · Common StockOther 10 759 @ $27,16$292K · 2026-01-23
- Director · Common StockOther 20 000 @ $5,79$116K · 2026-01-13
- Director · Common StockOther 4 269 @ $27,12$116K · 2026-01-13
- Chief Medical Officer · Common StockOther 5 102 @ $24,81$127K · 2026-01-01
- Director · Common StockOther 29 502 @ $17,78$525K · 2025-12-08
Short positioning
2.7Mshares short+0.2% vs prior
3.91days to cover
72.6%short of daily vol
365fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ASTH.WACanonical
Warsaw Stock Exchange · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Evidence & claims
From filings & derived data- Current ratio (FY 2025-12-31): 1.40xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 2.13xDerived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -12.1%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 119.5%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -49.5%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -52.0%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 25.8%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 9.3%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 97.5%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 133.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 63.8%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 56.4%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 48.9%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -48.9%Derived (calculated)
- Net margin (FY 2025-12-31): 0.8%Derived (calculated)
- Return on assets (FY 2025-12-31): 1.1%Derived (calculated)
- Return on equity (FY 2025-12-31): 3.1%Derived (calculated)
- Operating income (annual): USD 78.53MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 0SEC XBRL filing
- Cash & equivalents (annual): USD 429.47MSEC XBRL filing
- Shareholders' equity (annual): USD 779.29MSEC XBRL filing
- Pre-tax income (annual): USD 39.61MSEC XBRL filing
- Revenue (annual): USD 3.18BSEC XBRL filing
- Net income (annual): USD 24MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-02 08:12 UTCNEWSAstrana Health thesis revised after material 8-K filing → Handelsavisen analysis adjusts its stance on the healthcare software firm following a high-severity regulatory disclosure.
2026-07-02 04:32 UTCFILINGMaterial 8-K
2026-06-27INSIDERSim Brandon transacted 1.1k sh — CEO and President ~$49k
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-10 00:00 UTCINSIDER6 insider transactions — 2026-06
2026-06-10 00:00 UTCINSIDER6 insider transactions — 2026-06
2026-06-10INSIDERKitayama Mitchell W transacted 5.0k sh — Director
2026-06-10INSIDERChiang John transacted 4.5k sh — Director
2026-06-10INSIDERDai, Weili transacted 4.5k sh — Director
2026-06-10INSIDERDong Linda transacted 4.5k sh — Director
2026-06-10INSIDERMazdyasni Matthew transacted 4.5k sh — Director
2026-06-10INSIDERSchmidt David transacted 4.5k sh — Director
2026-05-16 00:00 UTCINSIDER1 insider transaction — 2026-05 · net sell $312k
2026-05-16 00:00 UTCINSIDER1 insider transaction — 2026-05 · net sell $312k
2026-05-16INSIDERBasho Chandan transacted 8.2k sh — COO and CFO ~$312k
2026-04-14 00:00 UTCINSIDER7 insider transactions — 2026-04 · net sell $1.6M
2026-04-14 00:00 UTCINSIDER7 insider transactions — 2026-04 · net sell $1.6M
2026-04-14INSIDERBasho Chandan transacted 3.9k sh — COO and CFO ~$113k
2026-04-06INSIDERLam Thomas S. transacted 41.7k sh — Director
2026-04-06INSIDERSim Brandon transacted 201.1k sh — CEO and President
2026-04-06INSIDERSim Kenneth T. transacted 100.0k sh — Director, Executive Chairman
2026-04-02INSIDERBasho Chandan transacted 2.1k sh — COO and CFO ~$52k
2026-04-01INSIDERKumar Dinesh M. transacted 58.0k sh — Chief Medical Officer ~$1.42M
2026-04-01INSIDERKumar Dinesh M. transacted 35.3k sh — Chief Medical Officer
2026-03-26 00:00 UTCINSIDER4 insider transactions — 2026-03 · net sell $322k
2026-03-26 00:00 UTCINSIDER4 insider transactions — 2026-03 · net sell $322k
2026-03-26INSIDERSobotka Glenn transacted 662 sh — Chief Accounting Officer ~$16k
2026-03-05INSIDERBasho Chandan transacted 1.2k sh — COO and CFO ~$31k
2026-03-05INSIDERLam Thomas S. transacted 9.3k sh — Director ~$232k
Showing the 40 most recent of 59 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage